报价延迟最少15分钟:2025/09/04 04:00 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9399
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.98/-0.62
|
|
企业价值
3.20M
|
| 资产负债 |
|
每股账面净值
0.80
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.74M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/04 04:00 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. |
